Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

Minerva Neurosciences (NERV) Change in Account Payables (2016 - 2026)

Minerva Neurosciences filings provide 2 years of Change in Account Payables readings, the most recent being $652706.0 for Q4 2021.

On a quarterly basis, Change in Account Payables rose 121.99% to $652706.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $857601.0, a 164.9% increase, with the full-year FY2025 number at -$1.1 million, down 436.27% from a year prior.
Change in Account Payables hit $652706.0 in Q4 2021 for Minerva Neurosciences, up from -$393188.0 in the prior quarter.
In the past five years, Change in Account Payables ranged from a high of $686050.0 in Q1 2020 to a low of -$2.4 million in Q3 2020.